Top

International Urology and Nephrology

Published in:

01-03-2016 | Nephrology - Original Paper

Fibroblast growth factor-23 but not sKlotho levels are related to diastolic dysfunction in type 1 diabetic patients with early diabetic nephropathy

Authors: Burcu Dogan, Izzet Hakki Arikan, Derya Guler, Nursen Keles, Banu Isbilen, Ferruh Isman, Aytekin Oguz

Published in: International Urology and Nephrology | Issue 3/2016

Abstract

Purpose

To investigate the soluble Klotho (sKlotho) and fibroblast growth factor-23 (FGF-23) levels and echocardiographic findings in type 1 diabetic patients with no or early diabetic nephropathy.

Methods

A total of 147 subjects (mean age 34.1 ± 9.2 years, 55.8 % were females) including type 1 diabetic patients with glomerular filtration rate (GFR) >60 ml/min (n = 71, mean age 34.3 ± 9.5 years, 54.9 % were females) and healthy controls (n = 76, mean age 33.9 ± 9.1 years, 56.6 % were females) were included in this study. Data on demographic characteristics, blood biochemistry, urinalysis, diabetes-related complications and echocardiography were recorded. Serum levels for sKlotho and FGF-23 were determined by ELISA method.

Results

Patient and control groups were similar in terms of mean sKlotho (509.2 ± 183.5 and 547.6 ± 424.0 pg/ml, respectively) and FGF-23 (76.2 ± 15.6 and 77.2 ± 15.1 pg/ml, respectively) levels as well as echocardiographic findings. No significant correlation of sKlotho (pg/ml) and FGF-23 (pg/ml) levels with cardiac parameters was noted among diabetic patients. In subgroup analysis, the correlations between FGF-23 levels and isovolumic relaxation time (ms) and early diastolic velocity at medial/septal annulus (E’med) (m/s) were significant only in patients with early diabetic nephropathy (DN) but not in non-DN patients. No significant association of sKlotho levels with echocardiographic findings was noted.

Conclusions

Our findings in young adult type 1 diabetic patients with GFR >60 ml/min versus healthy controls revealed no difference between groups in terms of sKlotho and FGF-23 levels and echocardiographic findings, while a significant correlation of FGF-23 (pg/ml) levels and diastolic dysfunction was noted only in patients with DN.

Koivisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J, Idzior-Walus B (1996) EURODIAB IDDM Complications Study Group. Cardiovascular disease and its risk factors in IDDM in Europe. Diabetes Care 19:689–697CrossRefPubMed

Brindisi MC, Bouillet B, Vergès B, Halimi S (2010) Cardiovascular complications in type 1 diabetes mellitus. Diabetes Metab 36:341–344 (Review) CrossRefPubMed

Shivalkar B, Dhondt D, Goovaerts I, Van Gaal L, Bartunek J, Van Crombrugge P, Vrints C (2006) Flow mediated dilatation and cardiac function in type 1 diabetes mellitus. Am J Cardiol 97:77–82CrossRefPubMed

Kacso IM, Bondor CI, Kacso G (2012) Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A. Clin Biochem 45:1415–1420CrossRefPubMed

Nakano C, Hamano T, Fujii N, Obi Y, Matsui I, Tomida K, Mikami S, Inoue K, Shimomura A, Nagasawa Y, Okada N, Tsubakihara Y, Rakugi H, Isaka Y (2012) Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone 50:1266–1274CrossRefPubMed

Donate-Correa J, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF (2012) FGF23/Klotho axis: phosphorus, mineral metabolism and beyond. Cytokine Growth Factor Rev 23:37–46CrossRefPubMed

Long YC, Kharitonenkov A (2011) Hormone-like fibroblast growth factors and metabolic regulation. Biochim Biophys Acta 1812:791–795CrossRefPubMed

Kurosu H, Kuro-O M (2009) The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 299:72–78CrossRefPubMed

Wang Y, Sun Z (2009) Current understanding of klotho. Ageing Res Rev. 8:43–51 (Review) PubMedCentralCrossRefPubMed

10.

Hu MC, Kuro-o M, Moe OW (2013) Renal and extrarenal actions of Klotho. Semin Nephrol. 33:118–129 (Review) PubMedCentralCrossRefPubMed

11.

Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435CrossRefPubMed

12.

Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M (2011) Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305:2432–2439PubMedCentralCrossRefPubMed

13.

Ix JH, Shlipak MG, Wassel CL, Whooley MA (2010) Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 25:993–997PubMedCentralCrossRefPubMed

14.

Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, Rifkin D, Siscovick DS, Sarnak MJ, Shlipak MG (2012) Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 60:200–207PubMedCentralCrossRefPubMed

15.

Jovanovich A, Ix JH, Gottdiener J, McFann K, Katz R, Kestenbaum B, de Boer IH, Sarnak M, Shlipak MG, Mukamal KJ, Siscovick D, Chonchol M (2013) Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis 231:114–119CrossRefPubMed

16.

Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393–4408PubMedCentralCrossRefPubMed

17.

Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE (2009) Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207:546–551CrossRefPubMed

18.

Mirza MA, Larsson A, Lind L, Larsson TE (2009) Circulating fibroblast growth factor- 23 is associated with vascular dysfunction in the community. Atherosclerosis 205:385–390CrossRefPubMed

19.

Pedersen L, Pedersen SM, Brasen CL, Rasmussen LM (2013) Soluble serum Klotho levels in healthy subjects. Comparison of two different immunoassays. Clin Biochem 46:1079–1083CrossRefPubMed

20.

Smith ER, McMahon LP, Holt SG (2013) Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs. Clin Chem Lab Med 51:1971–1981CrossRefPubMed

21.

Lacombe F, Dart A, Dewar E, Jennings G, Cameron J, Laufer E (1992) Arterial elastic properties in man: a comparison of echo-Doppler indices of aortic stiffness. Eur Heart J 13:1040–1045PubMed

22.

Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, Moe OW (2011) Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 22:124–136PubMedCentralCrossRefPubMed

23.

Devaraj S, Syed B, Chien A, Jialal I (2012) Validation of an immunoassay for soluble Klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease. Am J Clin Pathol 137:479–485CrossRefPubMed

24.

Zhao Y, Banerjee S, Dey N, LeJeune WS, Sarkar PS, Brobey R, Rosenblatt KP, Tilton RG, Choudhary S (2011) Klotho depletion contributes to increased inflammation in kidney of the db/db mouse model of diabetes via RelA (serine) 536 phosphorylation. Diabetes 60:1907–1916PubMedCentralCrossRefPubMed

25.

Cheng MF, Chen LJ, Cheng JY (2010) Decrease of Klotho in the kidney of streptozotocin induced diabetic rats. J Biomed Biotechnol 2010:513853PubMedCentralCrossRefPubMed

26.

Semba RD, Cappola AR, Sun K, Bandinelli S, Dalal M, Crasto C, Guralnik JM, Ferrucci L (2011) Plasma Klotho and cardiovascular disease in adults. J Am Geriatr Soc 59:1596–1601PubMedCentralCrossRefPubMed

27.

Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205–2215CrossRefPubMed

28.

Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB (2003) Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272–2279CrossRefPubMed

29.

Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T, Sugimura K, Kishimoto T, Kinoshita S, Kuroki T, Nabeshima Y (2001) Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 280:1015–1020CrossRefPubMed

30.

Yamazaki Y, Imura A, Urakawa I, Shimada T, Murakami J, Aono Y, Hasegawa H, Yamashita T, Nakatani K, Saito Y, Okamoto N, Kurumatani N, Namba N, Kitaoka T, Ozono K, Sakai T, Hataya H, Ichikawa S, Imel EA, Econs MJ, Nabeshima Y (2010) Establishment of sandwich ELISA for soluble alpha-Klotho measurement: age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun 398:513–518PubMedCentralCrossRefPubMed

31.

Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C (2010) FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 78:679–685CrossRefPubMed

32.

Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545–2552PubMedCentralCrossRefPubMed

33.

Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative metaanalysis. Lancet 375:2073–2081PubMedCentralCrossRefPubMed

34.

Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72:1004–1013CrossRefPubMed

35.

Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS (2006) Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21:1187–1196CrossRefPubMed

36.

Kazik A, Wilczek K, Polonski L (2010) Management of diastolic heart failure. Cardiol J 17:558–565PubMed

37.

Patil VC, Patil HV, Shah KB, Vasani JD, Shetty P (2011) Diastolic dysfunction in asymptomatic type 2 diabetes mellitus with normal systolic function. J Cardiovasc Dis Res 2:213–222PubMedCentralCrossRefPubMed

38.

Yancy CW, Lopatin M, Stevenson LW, DeMarco T, Fonarow GC (2006) ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Hearth Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47:76–84CrossRefPubMed

39.

Kardami E, Jiang ZS, Jimenez SK, Hirst CJ, Sheikh F, Zahradka P, Cattini PA (2004) Fibroblast growth factor 2 isoforms and cardiac hypertrophy. Cardiovasc Res 63:458–466CrossRefPubMed

40.

van Ark J, Hammes HP, van Dijk MC, Vervloet MG, Wolffenbuttel BH, van Goor H, Hillebrands JL (2013) Circulating alpha-klotho levels are not disturbed in patients with type 2 diabetes with and without macrovascular disease in the absence of nephropathy. Cardiovasc Diabetol 12:116PubMedCentralCrossRefPubMed

41.

Smith ER, Cai MM, McMahon LP, Holt SG (2012) Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 97:3357–3365CrossRefPubMed

Title: Fibroblast growth factor-23 but not sKlotho levels are related to diastolic dysfunction in type 1 diabetic patients with early diabetic nephropathy
Authors: Burcu Dogan
Izzet Hakki Arikan
Derya Guler
Nursen Keles
Banu Isbilen
Ferruh Isman
Aytekin Oguz
Publication date: 01-03-2016
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 3/2016
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-015-1190-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Fibroblast growth factor-23 but not sKlotho levels are related to diastolic dysfunction in type 1 diabetic patients with early diabetic nephropathy

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2016

Elevated levels of S100A12 in the seminal plasma of infertile men with varicocele

Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method

Neoplasm arising from the descended testis in a unilateral cryptorchid child: decisions and dilemmas

The impact of slow graft function on graft outcome is comparable to delayed graft function in deceased donor kidney transplantation

IgG4-related disease: what urologists should know

Effect of restricted protein diet supplemented with keto analogues in chronic kidney disease: a systematic review and meta-analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page